Gopten 4.0, 4 mg, hard capsules
Trandolapril
The active substance of Gopten 4.0 hard capsules is trandolapril. The medicine belongs to a group of angiotensin-converting enzyme inhibitors (ACE inhibitors). Trandolapril is rapidly absorbed from the gastrointestinal tract, and then in the liver, it is converted to a highly potent and long-acting active metabolite - trandolaprilat.
Administration of trandolapril in therapeutic doses to patients with arterial hypertension causes a significant decrease in arterial blood pressure measured in the patient in a lying and standing position.
The blood pressure-lowering effect appears after one hour and lasts for 24 hours, with maximum effect observed between the 8th and 12th hour after administration.
Gopten 4.0 is used in the treatment of:
Before starting treatment with Gopten 4.0, discuss it with your doctor, pharmacist, or nurse.
If you are to undergo surgery or anesthesia using drugs that cause hypotension.
Your doctor may recommend regular monitoring of kidney function, blood pressure, and electrolyte levels (e.g., potassium) in the blood.
See also the section "When not to take Gopten 4.0".
The safety and efficacy of Gopten 4.0 in children have not been studied, and therefore, its use is not recommended.
Tell your doctor or pharmacist about all medicines you are taking or have recently taken, as well as any medicines you plan to take.
Tell your doctor if you are taking any of the following medicines, as special caution is required:
In patients with left ventricular dysfunction after myocardial infarction, no clinically significant interactions were observed when Gopten 4.0 was administered concomitantly with:
Your doctor may recommend a dose change and/or other precautions:
Alcohol increases the risk of hypotension.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Tell your doctor if you suspect or plan to become pregnant. Your doctor will usually recommend stopping Gopten 4.0 before planned pregnancy or as soon as possible after confirmation of pregnancy and will recommend taking another medicine instead of Gopten 4.0.
fetus.
Tell your doctor if you are breastfeeding or plan to breastfeed. Gopten 4.0 should not be taken during breastfeeding, especially in newborns or premature infants. The doctor may recommend taking another medicine.
Gopten 4.0 may affect your ability to drive and use machines, especially during the initial treatment period, after changing your previous medicine, and when consuming alcohol.
It is not recommended to drive or operate machinery for a few hours after taking the first dose or after increasing the dose of the medicine.
If you have been diagnosed with intolerance to some sugars, contact your doctor before taking the medicine.
The medicine contains less than 1 mmol (23 mg) of sodium per tablet, which means it is considered "sodium-free".
Always take this medicine exactly as your doctor or pharmacist has told you. If you are not sure, ask your doctor or pharmacist.
Oral administration
Hypertension
In adult patients not taking diuretics, without congestive heart failure, and without kidney or liver disease, the recommended initial dose is 0.5 mg to 2 mg once daily. A dose of 0.5 mg is effective in only a small number of patients. In black patients, the initial dose is usually 2 mg. The dose should be gradually increased, every one to four weeks, depending on the patient's response to the medicine, until the maximum dose of 4 mg/day to 8 mg/day is reached.
The maintenance dose is usually 1 mg to 4 mg once daily. If the patient's response to a dose of 4 mg to 8 mg of trandolapril per day is not satisfactory, the doctor will consider concomitant administration of diuretics and/or calcium channel blockers.
Left ventricular dysfunction after myocardial infarction
Treatment can be started as early as the third day after myocardial infarction, with an initial dose of 0.5 mg to 1 mg once daily. The dose is gradually increased to a maximum of 4 mg once daily. Depending on the patient's response to the medicine (occurrence of symptomatic hypotension), the dose increase can be temporarily discontinued.
In case of hypotension, the doctor will recommend, if possible, reducing the dose of concomitantly administered vasodilators (including nitrates) and diuretics.
The dose of Gopten 4.0 can only be reduced if the above measures are ineffective or cannot be taken.
Elderly patients
In elderly patients with normal kidney and liver function, there is no need to reduce the dose.
Caution should be exercised in elderly patients treated concomitantly with diuretics, with congestive heart failure, or with kidney or liver disease. The dose is adjusted according to blood pressure values.
Patients taking diuretics
In dehydrated patients and those with sodium deficiency, the doctor may discontinue the diuretic 2-3 days before starting Gopten 4.0 to reduce the risk of symptomatic hypotension. If necessary, the diuretic can be restarted later.
Heart failure
Treatment should be started with a dose of 0.5 mg to 1 mg once daily, under close medical supervision.
Patients with kidney problems
In patients with a creatinine clearance (a measure of kidney function) of 30-70 ml/min, the recommended dose is the same as for adults, including the elderly.
In patients with a creatinine clearance below 30 ml/min, the recommended initial dose of trandolapril is 0.5 mg once daily, and the dose is gradually increased to achieve the desired effect. In these patients, treatment should be carried out under close medical supervision.
In patients with a creatinine clearance above 30 ml/min, there is no need to adjust the initial dose.
Dialysis patients
In dialysis patients, blood pressure should be carefully monitored, and the dose of Gopten 4.0 should be adjusted as needed.
Patients with liver problems
Treatment should be started with a dose of 0.5 mg once daily, under close medical supervision.
The safety and efficacy of Gopten 4.0 in children have not been studied, and therefore, its use is not recommended.
In case of overdose, the following symptoms may occur: severe hypotension, shock, stupor, slow heart rate, electrolyte disturbances, and kidney failure. After an overdose, the patient should be closely monitored, preferably in an intensive care unit. The doctor should frequently monitor electrolyte and creatinine levels in the blood. Treatment depends on the severity of symptoms. If the medicine was taken recently, the doctor will take measures to remove the medicine (e.g., induce vomiting, gastric lavage, administer absorbents, and sodium sulfate).
In case of symptomatic hypotension, the patient should be placed in a shock position as soon as possible. The doctor will administer appropriate treatment as soon as possible.
Do not take a double dose to make up for a forgotten dose.
Like all medicines, Gopten 4.0 can cause side effects, although not everybody gets them.
During clinical trials and after the marketing of Gopten 4.0, the following side effects have been observed:
Common(in 1 to 10 patients out of 100):
˗
headache, dizziness of central origin
˗
hypotension
˗
cough
˗
weakness
Uncommon(in 1 to 10 patients out of 1,000):
˗
upper respiratory tract infection
˗
insomnia, decreased libido
˗
drowsiness
˗
dizziness of peripheral origin
˗
palpitations (feeling of irregular or rapid heartbeat)
˗
flushing
˗
upper respiratory tract inflammation, nasal congestion
˗
nausea, diarrhea, abdominal pain, constipation, gastrointestinal disturbances
˗
rash, itching
˗
back pain, muscle cramps, limb pain
˗
erectile dysfunction
˗
malaise, chest pain, peripheral edema, feeling abnormal
Rare(in 1 to 10 patients out of 10,000):
˗
urinary tract infection, bronchitis, pharyngitis
˗
leukopenia (decrease in white blood cell count), anemia, blood platelet disorders, white blood cell disorders
˗
hypersensitivity
˗
abnormal laboratory test results: hyperglycemia (elevated blood sugar), hyponatremia (low sodium levels), hypercholesterolemia (elevated cholesterol), hyperlipidemia (elevated triglycerides and cholesterol), hyperuricemia (elevated uric acid)
˗
gout, anorexia, increased appetite, abnormal liver function tests
˗
hallucinations, depression, sleep disturbances, anxiety, agitation, apathy
˗
cerebrovascular incident, syncope, clonic muscle spasms, paresthesia (numbness, tingling of one or more limbs), migraine, migraine without aura, taste disturbances
˗
blepharitis, conjunctivitis, visual disturbances, eye disorders
˗
tinnitus
˗
myocardial infarction, myocardial ischemia, angina pectoris, heart failure, ventricular tachycardia, tachycardia, bradycardia
˗
hypertension, cerebrovascular disorders (angiopathy), orthostatic hypotension (sudden drop in blood pressure when changing position from lying to standing), peripheral vascular disorders, varicose veins
˗
dyspnea, epistaxis, pharyngitis, oropharyngeal pain, cough with expectoration, respiratory disorders
˗
hematemesis, gastritis, abdominal pain, vomiting, nausea, dry mouth, flatulence
˗
hepatitis
˗
angioedema, psoriasis, hyperhidrosis, urticaria, skin disorders
˗
arthralgia, myalgia, osteoarthritis
˗
kidney failure, azotemia (elevated nitrogen compounds in the blood), polyuria, frequent urination
˗
congenital vascular malformation, fish-scale skin
˗
edema, fatigue
˗
increased bilirubin levels (jaundice)
˗
injury
Very rare(in less than 1 patient out of 10,000):
˗
cholestasis (bile flow obstruction)
˗
skin inflammation
˗
abnormal laboratory test results (elevated γ-glutamyltransferase, elevated lipase, elevated immunoglobulins)
Side effects with unknownfrequency (frequency cannot be estimated from available data):
˗
sinusitis, rhinitis, glossitis
˗
pancytopenia (decrease in red, white, and platelet blood cell count), agranulocytosis (significant, rapidly progressing decrease in granulocyte count), thrombocytopenia (decrease in platelet count), hemolytic anemia
˗
hyperkalemia (elevated potassium levels)
˗
confusional state
˗
transient ischemic attack, cerebral hemorrhage, cerebrovascular disorders
˗
blurred vision
˗
atrioventricular block, arrhythmias, cardiac arrest
˗
bronchospasm
˗
intestinal obstruction, pancreatitis, angioedema of the intestines
˗
jaundice (yellowing of the skin and eyes)
˗
Stevens-Johnson syndrome, erythema multiforme, toxic epidermal necrolysis, urticaria, alopecia, psoriatic-like skin inflammation
˗
myalgia (muscle pain)
˗
fever
˗
abnormal laboratory test results (abnormal liver function tests, decreased platelet count, elevated creatinine, elevated urea, elevated lactate dehydrogenase, elevated alkaline phosphatase, elevated aspartate aminotransferase, elevated alanine aminotransferase, elevated liver enzymes, decreased hemoglobin, decreased hematocrit, abnormal ECG)
*Side effects related to ACE inhibitors as a class of medicines
Reporting side effects
If you experience any side effects, including those not listed in this leaflet, please inform your doctor or pharmacist. Side effects can be reported directly to the Department of Drug Safety Monitoring, Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: 22 49 21 301, fax: 22 49 21 309, website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
By reporting side effects, you can help provide more information on the safety of this medicine.
Do not store above 25°C.
Keep the medicine out of the sight and reach of children.
Do not use this medicine after the expiry date stated on the carton after "EXP" and on the blister after "EXP". The expiry date refers to the last day of the month.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
Gopten 4.0 is available in the form of hard capsules. The capsule cap is burgundy, and the body is red.
Packaging:
28 capsules.
PVC/PVDC/Aluminum blisters in a cardboard box.
Gopten 0.5, hard capsules, 0.5 mg, and Gopten 2.0, hard capsules, 2 mg, are also available on the market.
Viatris Healthcare Sp. z o.o.
ul. Postępu 21B
02-676 Warsaw
Mylan Hungary Kft.
Mylan utca 1.
Komárom, 2900
Hungary
To obtain more detailed information, please contact the marketing authorization holder:
Viatris Healthcare Sp. z o.o.
ul. Postępu 21B
02-676 Warsaw
tel.: (22) 546 64 00
Date of last revision of the leaflet:02/2024
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.